RBC Capital Reiterates Outperform Rating on AbbVie, Sets $280 Target
RBC Capital reiterated its Outperform rating on AbbVie and maintained a $280 price target, roughly in line with the stock's Oct. 12 close of $281.12.
RBC Capital reiterated its Outperform rating on AbbVie and maintained a $280 price target, roughly in line with the stock's Oct. 12 close of $281.12.